CTHRC1 Overexpression Predicts Poor Survival and Enhances Epithelial-mesenchymal Transition in Colorectal Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2018 Oct 11

PMID 30302922

Citations 39

Authors

Shujuan Ni

Fei Ren

Midie Xu

Cong Tan

Weiwei Weng

Zhaohui Huang

Weiqi Sheng

Dan Huang

Affiliations

Soon will be listed here.

Abstract

Collagen triple helix repeat containing (CTHRC1), which was identified as a cancer-related factor, is a promigratory protein involved in multiple processes, including vascular remodeling, antifibrosis, metabolism, bone formation, and cancer. In this study, we aimed to investigate the clinical significance and possible role of CTHRC1 in the process of epithelial-mesenchymal transition (EMT) in colorectal cancer (CRC). Here, we revealed that CTHRC1 mRNA and protein levels are both upregulated in CRC tissues compared with those of paired noncancerous tissues. Moreover, the overexpression of CTHRC1 correlated with poor prognosis in patients with CRC (especially colon cancer). Furthermore, we showed that CTHRC1 induced EMT and promoted cell motility in CRC cells. Importantly, we demonstrated that CTHRC1 promoted EMT by activating transforming growth factor-β (TGF-β) signaling, revealing a possible effective therapeutic treatment for patients with CRC.

Citing Articles

Single-cell and spatial transcriptome profiling reveal CTHRC1+ fibroblasts promote EMT through WNT5A signaling in colorectal cancer.

Lu Y, Chen Y, Wang Z, Shen H, Xu L, Huang C J Transl Med. 2025; 23(1):282.

PMID: 40050872 PMC: 11884118. DOI: 10.1186/s12967-025-06236-5.

Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer.

Malla M, Deshmukh S, Wu S, Samec T, Olevian D, El Naili R Cancer Gene Ther. 2024; 31(10):1547-1558.

PMID: 39174744 PMC: 11489080. DOI: 10.1038/s41417-024-00816-1.

CTHRC1 is associated with (V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma.

Zhang R, Wang Z, Wang H, Li L, Dong L, Ding L Biomol Biomed. 2024; 25(1):42-61.

PMID: 39052013 PMC: 11647256. DOI: 10.17305/bb.2024.10397.

CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis.

Mukhatayev Z, Adilbayeva A, Kunz J Cells. 2024; 13(11.

PMID: 38891078 PMC: 11171484. DOI: 10.3390/cells13110946.

Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.

Zhao Y, Li X, Loscalzo J, Smelik M, Sysoev O, Wang Y J Transl Med. 2024; 22(1):444.

PMID: 38734658 PMC: 11088765. DOI: 10.1186/s12967-024-05268-7.

References

Tameda M, Sugimoto K, Shiraki K, Yamamoto N, Okamoto R, Usui M . Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility. Int J Oncol. 2014; 45(2):541-8. PMC: 4091966. DOI: 10.3892/ijo.2014.2445. View

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

Ni S, Ren F, Xu M, Tan C, Weng W, Huang Z . CTHRC1 overexpression predicts poor survival and enhances epithelial-mesenchymal transition in colorectal cancer. Cancer Med. 2018; 7(11):5643-5654. PMC: 6247052. DOI: 10.1002/cam4.1807. View

Mittal V . Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018; 13:395-412. DOI: 10.1146/annurev-pathol-020117-043854. View

Tan F, Liu F, Liu H, Hu Y, Liu D, Li G . CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis. Med Oncol. 2013; 30(1):473. DOI: 10.1007/s12032-013-0473-3. View

Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S . Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell. 2008; 15(1):23-36. DOI: 10.1016/j.devcel.2008.05.007. View

Brabletz T, Kalluri R, Nieto M, Weinberg R . EMT in cancer. Nat Rev Cancer. 2018; 18(2):128-134. DOI: 10.1038/nrc.2017.118. View

Xu J, Lamouille S, Derynck R . TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19(2):156-72. PMC: 4720263. DOI: 10.1038/cr.2009.5. View

Kimura H, Kwan K, Zhang Z, Deng J, Darnay B, Behringer R . Cthrc1 is a positive regulator of osteoblastic bone formation. PLoS One. 2008; 3(9):e3174. PMC: 2527134. DOI: 10.1371/journal.pone.0003174. View

10.

Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S . Identification of the tumour transition states occurring during EMT. Nature. 2018; 556(7702):463-468. DOI: 10.1038/s41586-018-0040-3. View

11.

Wang P, Wang Y, Chen X, Shen Z, Cao H, Zhang Y . CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer. Cancer Sci. 2012; 103(7):1327-33. PMC: 7659176. DOI: 10.1111/j.1349-7006.2012.02292.x. View

12.

Eriksson J, Le Joncour V, Nummela P, Jahkola T, Virolainen S, Laakkonen P . Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget. 2016; 7(12):15065-92. PMC: 4924771. DOI: 10.18632/oncotarget.7604. View

13.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J . Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017; 17(2):79-92. DOI: 10.1038/nrc.2016.126. View

14.

Kye B, Jung J, Kim H, Kang S, Cho H, Kim J . Tumor budding as a risk factor of lymph node metastasis in submucosal invasive T1 colorectal carcinoma: a retrospective study. BMC Surg. 2012; 12:16. PMC: 3469500. DOI: 10.1186/1471-2482-12-16. View

15.

Bian Z, Miao Q, Zhong W, Zhang H, Wang Q, Peng Y . Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. J Autoimmun. 2015; 63:76-87. PMC: 4644665. DOI: 10.1016/j.jaut.2015.07.010. View

16.

Kim H, Kim Y, Oh H, Kim K, Oh S, Kim J . Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014; 5(2):519-29. PMC: 3964226. DOI: 10.18632/oncotarget.1714. View

17.

Gu L, Liu L, Zhong L, Bai Y, Sui H, Wei X . Cthrc1 overexpression is an independent prognostic marker in gastric cancer. Hum Pathol. 2014; 45(5):1031-8. DOI: 10.1016/j.humpath.2013.12.020. View

18.

Hou M, Cheng Z, Shen H, He S, Li Y, Pan Y . High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis. Oncotarget. 2015; 6(34):35813-29. PMC: 4742143. DOI: 10.18632/oncotarget.5358. View

19.

Kharaishvili G, Cizkova M, Bouchalova K, Mgebrishvili G, Kolar Z, Bouchal J . Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol. 2011; 64(11):977-82. DOI: 10.1136/jclinpath-2011-200106. View

20.

Tang L, Dai D, Su M, Martinka M, Li G, Zhou Y . Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006; 12(12):3716-22. DOI: 10.1158/1078-0432.CCR-06-0030. View